Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Verma, Subodh; David Mazer, C.; T. Yan, Andrew; Mason, Tamique; Garg, Vinay; Teoh, Hwee; Zuo, Fei; Quan, Adrian; E. Farkouh, Michael; H. Fitchett, David; G. Goodman, Shaun; M. Goldenberg, Ronald; Al-Omran, Mohammed; E. Gilbert, Richard; L. Bhatt, Deepak; A. Leiter, Lawrence; Jüni, Peter; Zinman, Bernard; A. Connelly, Kim; the EMPA-HEART CardioLink-6 Investigators, For

doi:10.1161/circulationaha.119.042375

Public

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Shared by NobleBlocks on Nov 19, 2019 • 12:00 AM UTC

Authors:

Subodh Verma

C. David Mazer

Andrew T. Yan

Abstract

Background: SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains unknown. We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with type 2 diabete...

Discussions